SPARTON CORP (SPA)

Overview Price 8.88 Price Change Today +$0.04 (+0.45%) P&P rating Zacks Rank 5 - STRONG SELL Open Price $8.84 Previous Close $8.84 Daily Range $8.71 - $8.95 52-Week Range $5.34 - $10.64 Volume 6,000 SPARTON CORP. 's continuing operations are principally in one line of business, the development and manufacture of electronic parts and assemblies. SPARTON CORP.'s products and services include microprocessor-based systems, transducers, printed circuit boards and assemblies, sensors and electronic and electromechanical contract manufacturing for the telecommunications, medical, electronics and other industries. Other Resources for SPA Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Stoneridge Beats, Profits Up May 7, 2012 Zacks Blog: Maxwell Gets Swiss Funding February 24, 2012 SPARTON CORP. 's continuing operations are principally in one line of business, the development and manufacture of electronic parts and assemblies. SPARTON CORP.'s products and services include microprocessor-based systems, transducers, printed circuit boards and assemblies, sensors and electronic and electromechanical contract manufacturing for the telecommunications, medical, electronics and other industries.   Brokerage Analyst Recommendations 1 Brokerage Firms Covering SPA   Strong Buy 1 Buy 0 Hold 0 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1   SPA Ratings: BUY  SELL  HOLD SPA Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 0 Buy 0 Sell   Top Buy Analysis No Buy Analysis. Be the First. More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
Zacks_Analysts	0.00	05/09/12	Isis??? Loss Widens on Higher Expenses - Analyst Blog	0
Zacks_Analysts	0.00	05/07/12	FDA Panel to Review Onyx Drug - Analyst Blog	0
Zacks_Analysts	0.00	04/03/12	Genzyme-Isis File Kynamro NDA - Analyst Blog	0
Zacks_Analysts	0.00	03/02/12	Isis Loss Widens; Focus on Kynamro - Analyst Blog	0
Zacks_Analysts	0.00	02/29/12	Onyx Pharma's MM Candidate Advances - Analyst Blog	0
Zacks_Analysts	0.00	02/24/12	Maxwell Gets Swiss Funding - Analyst Blog	0
Zacks_Analysts	0.00	01/24/12	Amiket, Another Key Value Driver for EpiCept - Analyst Blog	0
Zacks_Analysts	0.00	01/23/12	Galena Biopharma Initiates Phase III PRESENT Trial Of NeuVax Ahead of Schedule - Analyst Blog	0
Zacks_Analysts	0.00	11/30/11	Onyx' Cancer Drug on Right Track - Analyst Blog	0
Zacks_Analysts	0.00	10/04/11	Onyx Seeks Myeloma Drug Approval - Analyst Blog	0

Pages: [ 1 ]  2   3   4   5  >>

Commentary

There are no open picks with this stock at the moment.

Picks

There are no open picks with this stock at the moment.